ONEOK, Inc. (OKE) Stock Forecast
Data as of May 2, 2026Energy · Current price $90.77 (-1.83%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Mar 5, 2026 | Theresa Chan | Barclays | $82.00 | -9.7% |
| Jan 28, 2026 | Robert Kad | Morgan Stanley | $104.00 | +14.6% |
| Nov 3, 2025 | John Mackay | Goldman Sachs | $72.00 | -20.7% |
| Oct 30, 2025 | Selman Akyol | Stifel Nicolaus | $94.00 | +3.6% |
| Oct 30, 2025 | Michael Blum | Wells Fargo | $82.00 | -9.7% |
| Oct 9, 2025 | Theresa Chen | Barclays | $78.00 | -14.1% |
| Sep 29, 2025 | John Mackay | Goldman Sachs | $75.00 | -17.4% |
| Aug 14, 2025 | Theresa Chen | Barclays | $83.00 | -8.6% |
| Jul 15, 2025 | Holly Stewart | Scotiabank | $92.00 | +1.4% |
| Mar 25, 2025 | Robert Kad | Morgan Stanley | $133.00 | +46.5% |
| Oct 17, 2024 | Jean Ann Salisbury | Bank of America Securities | $105.00 | +15.7% |
| Oct 16, 2024 | Elvira Scotto | RBC Capital | $98.00 | +8.0% |
| Sep 16, 2024 | Robert Kad | Morgan Stanley | $111.00 | +22.3% |
| Sep 10, 2024 | Stewart Glickman | CFRA | $97.00 | +6.9% |
| Sep 3, 2024 | Spiro Dounis | Citigroup | $102.00 | +12.4% |
| Aug 7, 2024 | Stewart Glickman | CFRA | $90.00 | -0.8% |
| Jul 30, 2024 | Neal Dingmann | Truist Financial | $83.00 | -8.6% |
| Jul 30, 2024 | Sunil Sibal | Seaport Global | $89.00 | -1.9% |
| Feb 8, 2024 | Sunil Sibal | Seaport Global | $76.00 | -16.3% |
| Oct 2, 2023 | Sector Outperform | Scotiabank | $78.00 | -14.1% |
Top Analysts Covering OKE
OKE vs Sector & Market
| Metric | OKE | Energy Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.56 | 2.53 | 2.41 |
| Analyst Count | 18 | 10 | 18 |
| Target Upside | -1.0% | +33.7% | +14.9% |
| P/E Ratio | 16.18 | 30.85 | 31.19 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $29.47B | $35.01B | $41.02B | 7 |
| 2027-12-31 | $30.53B | $36.26B | $42.51B | 6 |
| 2028-12-31 | $35.90B | $35.99B | $36.09B | 7 |
| 2029-03-31 | $13.82B | $17.25B | $20.26B | 3 |
| 2029-06-30 | $14.52B | $18.12B | $21.29B | 2 |
| 2029-09-30 | $15.26B | $19.04B | $22.37B | 2 |
| 2029-12-31 | $16.03B | $20.00B | $23.50B | 3 |
| 2030-03-31 | $16.84B | $21.02B | $24.70B | 3 |
| 2030-06-30 | $17.70B | $22.09B | $25.95B | 2 |
| 2030-09-30 | $18.60B | $23.21B | $27.27B | 2 |
| 2030-12-31 | $19.54B | $24.38B | $28.65B | 3 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $5.50 | $5.71 | $5.92 | 10 |
| 2027-12-31 | $5.95 | $6.19 | $6.42 | 9 |
| 2028-12-31 | $6.23 | $6.72 | $7.44 | 8 |
| 2029-03-31 | $1.26 | $1.70 | $2.08 | 4 |
| 2029-06-30 | $1.28 | $1.73 | $2.13 | 2 |
| 2029-09-30 | $1.36 | $1.84 | $2.25 | 2 |
| 2029-12-31 | $1.41 | $1.89 | $2.33 | 2 |
| 2030-03-31 | $1.34 | $1.80 | $2.21 | 2 |
| 2030-06-30 | $1.39 | $1.88 | $2.31 | 2 |
| 2030-09-30 | $1.44 | $1.94 | $2.38 | 5 |
| 2030-12-31 | $1.45 | $1.95 | $2.40 | 5 |
Frequently Asked Questions
What is the analyst consensus for OKE?
The consensus among 18 analysts covering ONEOK, Inc. (OKE) is Hold with an average price target of $87.90.
What is the highest price target for OKE?
The highest price target for OKE is $133.00, set by Robert Kad at Morgan Stanley on 2025-03-25.
What is the lowest price target for OKE?
The lowest price target for OKE is $57.00, set by Mirek Zak at Neuberger Berman on 2021-06-08.
How many analysts cover OKE?
18 analysts have issued ratings for ONEOK, Inc. in the past 12 months.
Is OKE a buy or sell right now?
Based on 18 analyst ratings, OKE has a consensus rating of Hold (2.56/5) with a -1.0% upside to the consensus target of $87.90.
What are the earnings estimates for OKE?
Analysts estimate OKE will report EPS of $5.71 for the period ending 2026-12-31, with revenue estimated at $35.01B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.